In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Ocular Therapeutix Inc’s stock clocked out at $4.74, up 12.98% from its previous closing price of $4.20. In other words, the price has increased by $12.98 from its previous closing price. On the day, 3.88 million shares were traded. OCUL stock price reached its highest trading level at $4.79 during the session, while it also had its lowest trading level at $4.06.
Ratios:
To gain a deeper understanding of OCUL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.59 and its Current Ratio is at 6.66. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.90.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on February 09, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On April 21, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $18.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 26 ’24 when SUMMER ROAD LLC bought 930,851 shares for $7.52 per share. The transaction valued at 7,000,000 led to the insider holds 8,591,401 shares of the business.
Mattessich Antony C. sold 18,338 shares of OCUL for $90,773 on Jan 31 ’24. The President and CEO now owns 427,943 shares after completing the transaction at $4.95 per share. On Jan 31 ’24, another insider, Ozden Rabia Gurses, who serves as the Chief Medical Officer of the company, sold 7,764 shares for $4.95 each. As a result, the insider received 38,432 and left with 92,767 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 705235136 and an Enterprise Value of 592819200. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.07 while its Price-to-Book (P/B) ratio in mrq is 5.99. Its current Enterprise Value per Revenue stands at 10.144 whereas that against EBITDA is -7.466.
Stock Price History:
Over the past 52 weeks, OCUL has reached a high of $11.31, while it has fallen to a 52-week low of $2.00. The 50-Day Moving Average of the stock is -44.58%, while the 200-Day Moving Average is calculated to be -3.49%.
Shares Statistics:
It appears that OCUL traded 2.43M shares on average per day over the past three months and 3758670 shares per day over the past ten days. A total of 148.63M shares are outstanding, with a floating share count of 135.05M. Insiders hold about 9.13% of the company’s shares, while institutions hold 45.08% stake in the company. Shares short for OCUL as of 1713139200 were 14646476 with a Short Ratio of 6.02, compared to 1710460800 on 9163734. Therefore, it implies a Short% of Shares Outstanding of 14646476 and a Short% of Float of 10.31.
